3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazole-5-carbaldehyde | 76799-25-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并恶唑类
• 英文名称: 3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazole-5-carbaldehyde
• 英文别名: 3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazole-5-carbaldehyde；3-methyl-2-oxo-1,3-benzoxazole-5-carbaldehyde
• CAS: 76799-25-2
• 化学式: C₉H₇NO₃
• 分子量: 177.159
• InChiKey: REYHUPOYMVCTTA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES BICYCLIQUES SUBSTITUÉS
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2017184662A1

  公开（公告）日：2017-10-26

  Disclosed are compounds of Formula (I), or a salt thereof, wherein: X is CR4 or N; Y is CR4 or N, provided that Y is N only if X is N; R1 is Formulae (A) or (B); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, R3, R4, L1, R1a, R1b, R1c, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

  揭示了Formula (I)的化合物或其盐，其中：X为CR4或N；Y为CR4或N，但仅当X为N时，Y才为N；R1为Formulae (A)或(B)；每个W独立地为NR1b或O；Z为键或CHR1d；R1、R2、R3、R4、L1、R1a、R1b、R1c和n在此有定义。还揭示了将这些化合物用作ROMK的抑制剂的方法，以及包含这些化合物的药物组合物。这些化合物在治疗心血管疾病方面是有用的。
• Substituted bicyclic heterocyclic compounds
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US10851108B2

  公开（公告）日：2020-12-01

  Disclosed are compounds of Formula (I), or a salt thereof, wherein: X is CR4 or N; Y is CR4 or N, provided that Y is N only if X is N; R1 is Formulae (A) or (B); each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, R3, R4, L1, R1a, R1b, R1c, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.

  公开了式(I)化合物或其盐，其中：X是CR4或N；Y是CR4或N，但只有当X是N时Y才是N；R1是式(A)或(B)；每个W独立地是NR1b或O；Z是键或CHR1d；以及R1、R2、R3、R4、L1、R1a、R1b、R1c和n在本文中定义。还公开了使用此类化合物作为 ROMK 抑制剂的方法，以及包含此类化合物的药物组合物。这些化合物可用于治疗心血管疾病。
• SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20190127380A1

  公开（公告）日：2019-05-02

  Disclosed are compounds of Formula (I), or a salt thereof, wherein: X is CR 4 or N; Y is CR 4 or N, provided that Y is N only if X is N; R 1 is Formulae (A) or (B); each W is independently NR 1b or O; Z is a bond or CHR 1d ; and R 1 , R 2 , R 3 , R 4 , L 1 , R 1a , R 1b , R 1c , and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.
• INHIBITORS OF APOL1 AND METHODS OF USING SAME
  申请人：Vertex Pharmaceuticals Incorporated

  公开号：US20220106327A1

  公开（公告）日：2022-04-07

  The disclosure provides at least one entity chosen from compounds of Formula I, a tautomer thereof, a deuterated derivative of that compound or tautomer, and a pharmaceutically acceptable salt of any of the foregoing, compositions comprising the same, and methods of using the same, including uses in treating APOL1-mediated diseases, including pancreatic cancer, focal segmental glomerulosclerosis (FSGS), and/or non-diabetic kidney disease (NDKD).